Details
Stereochemistry | ACHIRAL |
Molecular Formula | C23H28ClN3O5S |
Molecular Weight | 494.004 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=C(C=C(Cl)C=C1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3
InChI
InChIKey=ZNNLBTZKUZBEKO-UHFFFAOYSA-N
InChI=1S/C23H28ClN3O5S/c1-32-21-12-9-17(24)15-20(21)22(28)25-14-13-16-7-10-19(11-8-16)33(30,31)27-23(29)26-18-5-3-2-4-6-18/h7-12,15,18H,2-6,13-14H2,1H3,(H,25,28)(H2,26,27,29)
Molecular Formula | C23H28ClN3O5S |
Molecular Weight | 494.004 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:05:50 UTC 2023
by
admin
on
Fri Dec 15 15:05:50 UTC 2023
|
Record UNII |
SX6K58TVWC
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000008054
Created by
admin on Fri Dec 15 15:05:50 UTC 2023 , Edited by admin on Fri Dec 15 15:05:50 UTC 2023
|
||
|
NDF-RT |
N0000008054
Created by
admin on Fri Dec 15 15:05:50 UTC 2023 , Edited by admin on Fri Dec 15 15:05:50 UTC 2023
|
||
|
FDA ORPHAN DRUG |
502615
Created by
admin on Fri Dec 15 15:05:50 UTC 2023 , Edited by admin on Fri Dec 15 15:05:50 UTC 2023
|
||
|
FDA ORPHAN DRUG |
518816
Created by
admin on Fri Dec 15 15:05:50 UTC 2023 , Edited by admin on Fri Dec 15 15:05:50 UTC 2023
|
||
|
LIVERTOX |
463
Created by
admin on Fri Dec 15 15:05:50 UTC 2023 , Edited by admin on Fri Dec 15 15:05:50 UTC 2023
|
||
|
WHO-VATC |
QA10BB01
Created by
admin on Fri Dec 15 15:05:50 UTC 2023 , Edited by admin on Fri Dec 15 15:05:50 UTC 2023
|
||
|
NDF-RT |
N0000175608
Created by
admin on Fri Dec 15 15:05:50 UTC 2023 , Edited by admin on Fri Dec 15 15:05:50 UTC 2023
|
||
|
FDA ORPHAN DRUG |
539316
Created by
admin on Fri Dec 15 15:05:50 UTC 2023 , Edited by admin on Fri Dec 15 15:05:50 UTC 2023
|
||
|
NDF-RT |
N0000008054
Created by
admin on Fri Dec 15 15:05:50 UTC 2023 , Edited by admin on Fri Dec 15 15:05:50 UTC 2023
|
||
|
FDA ORPHAN DRUG |
491215
Created by
admin on Fri Dec 15 15:05:50 UTC 2023 , Edited by admin on Fri Dec 15 15:05:50 UTC 2023
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
18.5
Created by
admin on Fri Dec 15 15:05:50 UTC 2023 , Edited by admin on Fri Dec 15 15:05:50 UTC 2023
|
||
|
EU-Orphan Drug |
EU/3/15/1589
Created by
admin on Fri Dec 15 15:05:50 UTC 2023 , Edited by admin on Fri Dec 15 15:05:50 UTC 2023
|
||
|
NCI_THESAURUS |
C97936
Created by
admin on Fri Dec 15 15:05:50 UTC 2023 , Edited by admin on Fri Dec 15 15:05:50 UTC 2023
|
||
|
WHO-ATC |
A10BB01
Created by
admin on Fri Dec 15 15:05:50 UTC 2023 , Edited by admin on Fri Dec 15 15:05:50 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB07916MIG
Created by
admin on Fri Dec 15 15:05:50 UTC 2023 , Edited by admin on Fri Dec 15 15:05:50 UTC 2023
|
PRIMARY | |||
|
2386
Created by
admin on Fri Dec 15 15:05:50 UTC 2023 , Edited by admin on Fri Dec 15 15:05:50 UTC 2023
|
PRIMARY | |||
|
GLYBURIDE
Created by
admin on Fri Dec 15 15:05:50 UTC 2023 , Edited by admin on Fri Dec 15 15:05:50 UTC 2023
|
PRIMARY | Description: A white or almost white, crystalline powder; odourless or almost odourless. Solubility: Practically insoluble in water and ether R; slightly soluble in ethanol (~750 g/l) TS and methanol R. Category: Antidiabetic agent. Storage: Glibenclamide should be kept in a well-closed container. Definition: Glibenclamide contains not less than 98.5% and not more than 101.0% of C23H28ClN3O5S, calculated with reference to the dried substance. | ||
|
1314
Created by
admin on Fri Dec 15 15:05:50 UTC 2023 , Edited by admin on Fri Dec 15 15:05:50 UTC 2023
|
PRIMARY | |||
|
759618
Created by
admin on Fri Dec 15 15:05:50 UTC 2023 , Edited by admin on Fri Dec 15 15:05:50 UTC 2023
|
PRIMARY | |||
|
m5784
Created by
admin on Fri Dec 15 15:05:50 UTC 2023 , Edited by admin on Fri Dec 15 15:05:50 UTC 2023
|
PRIMARY | Merck Index | ||
|
SX6K58TVWC
Created by
admin on Fri Dec 15 15:05:50 UTC 2023 , Edited by admin on Fri Dec 15 15:05:50 UTC 2023
|
PRIMARY | |||
|
5441
Created by
admin on Fri Dec 15 15:05:50 UTC 2023 , Edited by admin on Fri Dec 15 15:05:50 UTC 2023
|
PRIMARY | |||
|
Glyburide
Created by
admin on Fri Dec 15 15:05:50 UTC 2023 , Edited by admin on Fri Dec 15 15:05:50 UTC 2023
|
PRIMARY | |||
|
3488
Created by
admin on Fri Dec 15 15:05:50 UTC 2023 , Edited by admin on Fri Dec 15 15:05:50 UTC 2023
|
PRIMARY | |||
|
10238-21-8
Created by
admin on Fri Dec 15 15:05:50 UTC 2023 , Edited by admin on Fri Dec 15 15:05:50 UTC 2023
|
PRIMARY | |||
|
SX6K58TVWC
Created by
admin on Fri Dec 15 15:05:50 UTC 2023 , Edited by admin on Fri Dec 15 15:05:50 UTC 2023
|
PRIMARY | |||
|
233-570-6
Created by
admin on Fri Dec 15 15:05:50 UTC 2023 , Edited by admin on Fri Dec 15 15:05:50 UTC 2023
|
PRIMARY | |||
|
100000080403
Created by
admin on Fri Dec 15 15:05:50 UTC 2023 , Edited by admin on Fri Dec 15 15:05:50 UTC 2023
|
PRIMARY | |||
|
D005905
Created by
admin on Fri Dec 15 15:05:50 UTC 2023 , Edited by admin on Fri Dec 15 15:05:50 UTC 2023
|
PRIMARY | |||
|
1295505
Created by
admin on Fri Dec 15 15:05:50 UTC 2023 , Edited by admin on Fri Dec 15 15:05:50 UTC 2023
|
PRIMARY | |||
|
2414
Created by
admin on Fri Dec 15 15:05:50 UTC 2023 , Edited by admin on Fri Dec 15 15:05:50 UTC 2023
|
PRIMARY | |||
|
GLIBENCLAMIDE
Created by
admin on Fri Dec 15 15:05:50 UTC 2023 , Edited by admin on Fri Dec 15 15:05:50 UTC 2023
|
PRIMARY | |||
|
DB01016
Created by
admin on Fri Dec 15 15:05:50 UTC 2023 , Edited by admin on Fri Dec 15 15:05:50 UTC 2023
|
PRIMARY | |||
|
4815
Created by
admin on Fri Dec 15 15:05:50 UTC 2023 , Edited by admin on Fri Dec 15 15:05:50 UTC 2023
|
PRIMARY | RxNorm | ||
|
DTXSID0037237
Created by
admin on Fri Dec 15 15:05:50 UTC 2023 , Edited by admin on Fri Dec 15 15:05:50 UTC 2023
|
PRIMARY | |||
|
C29076
Created by
admin on Fri Dec 15 15:05:50 UTC 2023 , Edited by admin on Fri Dec 15 15:05:50 UTC 2023
|
PRIMARY | |||
|
CHEMBL472
Created by
admin on Fri Dec 15 15:05:50 UTC 2023 , Edited by admin on Fri Dec 15 15:05:50 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TRANSPORTER -> INHIBITOR | |||
|
PARENT->INNOVATOR |
|
||
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
||
|
TARGET -> INHIBITOR |
Glyburide stimulates insulin secretion through the closure of ATP-sensitive potassium channels decrease the K+ permeability of the cell membrane which leads to a depolarization of the cell, an enhanced Ca 2+ influx and the release of insulin
|
||
|
TRANSPORTER -> INHIBITOR | |||
|
TRANSPORTER -> INHIBITOR |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT |
1/400 as active as the parent in rat
URINE
|
||
|
METABOLITE -> PARENT |
1/40 as active as the parent in rat
URINE
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
|
||
|
IMPURITY -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||